Royal Philips

Zenition 30 marks the latest addition to the company’s versatile Zenition mobile C-arm series. The Amsterdam-based company unveiled its Zenition 10 version earlier this year. The mobile-C arm X-ray systems provide live image guidance during a range of clinical procedures in the operating room. They contribute to orthopedics, trauma, spine, pain management and other surgical procedures.

Philips said in a news release that Zenition 30 offers surgeons a greater level of control, autonomy and independence in these operations. By reducing dependency on support staff, Zenition 30 helps to alleviate the staff shortages faced by many hospitals. It also features workflow enhancements and high-quality images that enable high-quality care …

CoxHealth, a U.S. not-for-profit healthcare provider, sought out Philips to implement virtual care through its hospital network. The company wanted a solution staffed entirely by its own employees that expanded beyond the intensive care unit. It also hoped for something that allowed nurses and physicians to move seamlessly between the bedside and virtual environments.

Along with the increased adoption of telehealth and virtual care during the COVID-19 pandemic, these aims led to a collaboration. CoxHealth wanted to work with Philips to go beyond an eICU program.

Together, the two created a solution based on the close integration of the Philips eCareManager enterprise health software and Philips Capsule Surveillance. Using AI and advanced clinical algori…

The trial aims to evaluate whether a direct-to-angio suite (DTAS) workflow can improve outcomes for early time-window stroke patients. It compares this method to the conventional approach that uses a diagnostic MR/CT scan before transfer to the angio suite.

The Bicêtre Hospital in Paris successfully recruited the first French patient in the WE-TRUST trial. The Baptist Stroke & Cerebrovascular Center in Jacksonville, Florida, successfully enrolled the first patient in the U.S. Philips said these enrollments mark the important international expansion of the WE-TRUST trial. The company already has patients enrolled in Europe and South America, including in Spain, Turkey, Germany, Brazil, The Netherlands and Argentina.

Philips (NYSE: PHG) + announced that it plans to repurchase up to 7.1 million shares.

The Amsterdam-based medtech giant initiated this repurchase effort to cover certain obligations arising from long-term incentive plans. At the current share price, 7.1 million shares equals approximately $148.3 million (€132 million).

Philips said it plans to execute its repurchases through one or more individual forward transactions. The company expects these to take place in the second and/or third quarter of 2023. They must fall in accordance with the Market Abuse Regulation.

According to Philips, its repurchases must also land within the limits of the authorization granted by the company’s general shareholders meeting. The company held that meeting on May 9.

Philips anticipates taking delivery of the shares in 2024 and 2025.

Shares of PHG rose 0.1% at $22.75 apiece in midday trading today. MassDeviceR…

The notice warns of an issue that may occur due to forces applied during the movement of the C-Arc for Allura and Azurion. Philips’ image-guided therapy systems may experience loosening or breaking in their FlexMove carriage as a result. Cracks may also occur in the FlexMove carriage.

If FlexMove rail fixation bolts become loose or broken, cracks appear and a range of issues may occur. That includes the stopping of the C-Arc’s transversal movements due to false collision detections from additional friction. The issue may also disable manual movement because of the added friction. Abnormal noise, unstable suspension and falling of the C-Arc may also occur.

Loss of the mechanical movements of the C-Arc duri…

Amsterdam-based Philips had results of the health economic analysis published in the Journal of NeuroInterventional Surgery (JNIS). Data demonstrated that the company’s approach to stroke care reduced costs by an average of $3,120 per patient.

Philips’ retrospective analysis looked at data from the controlled, single-center ANGIOCAT clinical trial. Investigators at the Vall d’Hebron University Hospital Stroke Unit (Barcelona, Spain) conducted the study. Earlier results showed that a “direct-to-angio suite” pathway also improves clinical outcomes for patients who suffered a stroke.

“The ANGIOCAT clinical study has already shown that bringing stroke patients directly to the angio suite improves patient outcomes. The ec…

Amsterdam-based Philips designed the new CT system to target the needs of routine radiology and high-volume screening programs. It features a range of image-reconstruction and workflow-enhancing features to deliver consistency, speed and first-time-right image quality.

The company said it enables confident diagnoses by clinicians and increased return on investment in demanding, high-volume care settings.

“Increased financial pressures, chronic staff shortages, and escalating patient demand are driving radiology departments to do everything they can to maximize throughput, to guarantee equipment uptime, and to avoid repeat scans,” said Frans Venker, GM, computed tomography at Philips. “Today, many radiology departments scan hundreds of patients a day. We’ve engineered the Philips C…

Royal Philips shareholders voiced their displeasure with management’s handling of the company’s massive respiratory device recall at the annual meeting this week.

Shareholders voted down a proposal to relieve the board of management of liability, keeping the potential for investor lawsuits related to the Philips Respironics recall on the table.

“This follows the voting guidance from certain proxy advisors to signal discontent in respect of one former member of the Board of Management,” the company said in a news release, without naming that member.

“We appreciate the support expressed by the shareholders regarding current management and direction of Philips,” Royal Philips Supervisory Board Chair Feike Sijbesma said in the release. “Under the leadership of its new CEO Roy Jakobs, Philips is fully focused on implementing the plan to create value with sustainable impact for our shareholders and all other stakeholde…

The latest edition to the Zenition mobile C-arm series helps to expand patient access to routine surgical care and minimally invasive procedures. Now commercially available, the Zenition 10 utilizes Philips’ state-of-the-art flat panel detector technology for cost-effective, high-quality imaging.

Philips says the mobile C-arm enables surgeons to treat more patients at lower costs while improving outcomes.

“Philips Zenition mobile C-arms have long been recognized for their high-quality imaging and efficiency-enhancing performance. “With the introduction of Zenition 10, we are making those benefits available on a C-arm that meets the wide-ranging needs of routine open and minimally invas…